Enzo Biochem (NYSE:ENZ) Earns Hold Rating from Analysts at StockNews.com

Equities research analysts at StockNews.com started coverage on shares of Enzo Biochem (NYSE:ENZ) in a research note issued on Sunday. The brokerage set a “hold” rating on the medical research company’s stock.

Enzo Biochem Stock Down 14.8%

Enzo Biochem stock opened at $0.33 on Friday. Enzo Biochem has a 12-month low of $0.25 and a 12-month high of $1.28. The firm’s fifty day moving average price is $0.36 and its 200 day moving average price is $0.63.

Enzo Biochem (NYSE:ENZ) last released its quarterly earnings results on Monday, March 17th. The medical research company reported ($0.02) earnings per share (EPS) for the quarter. Enzo Biochem had a negative return on equity of 7.96% and a negative net margin of 75.34%. The firm had revenue of $7.33 million for the quarter.

Institutional Investors Weigh In On Enzo Biochem

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Mink Brook Asset Management LLC acquired a new position in Enzo Biochem during the 4th quarter worth $577,000. Lepercq Multi Asset Fund acquired a new position in Enzo Biochem during the 4th quarter worth $88,000. Wittenberg Investment Management Inc. grew its holdings in Enzo Biochem by 46.2% during the 1st quarter. Wittenberg Investment Management Inc. now owns 274,095 shares of the medical research company’s stock worth $101,000 after acquiring an additional 86,558 shares in the last quarter. Virtu Financial LLC acquired a new position in Enzo Biochem during the 4th quarter worth $35,000. Finally, Lepercq De Neuflize Asset Management LLC grew its holdings in Enzo Biochem by 27.1% during the 1st quarter. Lepercq De Neuflize Asset Management LLC now owns 156,303 shares of the medical research company’s stock worth $58,000 after acquiring an additional 33,303 shares in the last quarter. Hedge funds and other institutional investors own 36.90% of the company’s stock.

Enzo Biochem Company Profile

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.